ImpediMed (ASX:IPD) said that the increase in its US sales in the fiscal fourth quarter qualified it for an additional tranche 2 funding of $5 million under a capital growth facility with SWK Funding, according to a Wednesday Australian bourse filing.
US sales for the June quarter came in at 44 units, rising 100% from the previous quarter and 91% from the year-ago quarter. The total contract value for the fiscal fourth quarter came in at AU$6.3 million, jumping 29% from the prior quarter.
The firm executed an agreement for a five-year $15 million growth capital debt facility with SWK Funding in February. Funds under the facility will be used to support growth and commercialization activities.
Its shares jumped 13% on market close.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。